Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 9/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 9/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 9/20 | 1.00 |
| ▸ | GRIK5 | Q16478 | 9/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.69 |
| ▸ | DTYMK | P23919 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648446 | 1.00 | GRIA1 (1.00) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL13184606 | 0.84 | GRIA1 (0.72) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL401659 | 0.82 | GRIA1 (1.00) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL8631021 | 0.82 | GRIA1 (0.69) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL8296644 | 0.82 | GRIA1 (1.00) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL5000789 | 0.82 | GRIA1 (1.00) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL13957600 | 0.82 | GRIA1 (0.69) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL2153060 | 0.76 | GRIA1 (0.60) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL19873722 | 0.73 | DTYMK (0.58) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| (S)-Willardiine SCHEMBL438494 | 0.72 | GRIA1 (0.56) | GRIA1GRIA2GRIA4GRIK5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022138943-A1 | PRODUCTION METHOD FOR NON-HUMAN MODEL ANIMAL WITH MENTAL DISORDER OR NEUROLOGICAL DISORDER, SAID NON-HUMAN MODEL ANIMAL, AND METHOD FOR SCREENING FOR PROPHYLACTIC OR THERAPEUTIC AGENT FOR SAID MENTAL DISORDER OR NEUROLOGICAL DISORDER | 公立大学法人横浜市立大学 | 2022-06-30 | — | — | WO | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2018204764-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |